> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Repligen CEO Says Equipment 'Tap' Is Only 5-10% Open, Even After Five-Year High In Orders
- URL: https://www.bullished.co/repligen-ceo-says-equipment-tap-is-only-5-10-open-even-after-five-year-high-in-orders-cd78f39d/
- Published: 2026-10-27T13:26:54.000Z
- Updated: 2026-10-29T18:20:38.000Z
- Description: Capital equipment orders rose mid-teens, but buyers are slow to commit, so most of the revenue lands in 2027, the CEO said.
- Author: Matteo Parrino
- Tags: Earnings, RGEN, Industry: Healthcare

[Repligen](https://www.bullished.co/tag/rgen/)'s capital equipment orders rose mid-teens year over year in the third quarter, the highest order quarter in five years, CEO Olivier Loeillot said on the company's [earnings call](https://www.globenewswire.com/news-release/2026/10/27/3388843/24603/en/repligen-reports-third-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance.html?ref=bullished.co) on Tuesday. Equipment revenue still declined, because customers want delivery in 2027.

## Orders up, revenue pushed out

Repligen, which makes the filtration, chromatography, analytics and protein products biopharma companies use to manufacture biologic drugs, reported record quarterly revenue of [$209 million](https://www.globenewswire.com/news-release/2026/10/27/3388843/24603/en/repligen-reports-third-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance.html?ref=bullished.co), up 12.5% on an organic basis. Most equipment sits in its filtration franchise, where revenue fell 11% in the quarter. That decline included a two-point hit from the PolyMem divestiture and currency, and was slightly worse than management expected.

Loeillot tied the shortfall largely to timing: most system orders are slated for delivery in 2027 at customers' request. He also pointed to the previously disclosed headwind in its ATF filtration line, which was most pronounced in the quarter. Management now expects filtration to be flat to slightly down for the year.

Responding to a UBS analyst, Loeillot said equipment orders are all set for recognition in 2027, and that the company will enter the year with a much stronger equipment backlog than it had entering 2026.

## The tap and the funnel

On equipment, Loeillot said "even with the tap probably being only 5-10% open," Repligen delivered the highest quarter of capital equipment orders in its history. Asked whether decision-making is still being delayed, he said: "The answer is yes, absolutely." The funnel is the highest the company has had on the equipment side, he said, but the speed at which customers place orders is lacking.

He named two swing factors for market growth next year: a fuller pickup in capital equipment, and more FDA approvals, which have been stronger in cell and gene therapy than in monoclonal antibodies and biosimilars.

Services offered a brighter spot. Loeillot said systems under service contract rose nearly 40% this year despite the muted equipment revenue environment, and services made up 7% of third-quarter revenue.

## Guidance and the BioLife deal

Repligen raised its 2026 revenue guidance to $844 million to $852 million, including about $24 million from BioLife, which it closed on October 6\. Organic growth is now forecast at 12% to 13%, and adjusted earnings per share at [$2.05 to $2.09](https://finance.yahoo.com/markets/stocks/articles/repligen-q3-earnings-snapshot-110935702.html?ref=bullished.co).

Loeillot said that, assuming market growth in the high single digits, the BioLife deal positions Repligen to grow reported revenue at least 25% next year, absent a material change in exchange rates, pushing it past $1 billion. He stressed this is not formal 2027 guidance; the company plans to give that around the end of February.

Loeillot said Repligen will give formal 2027 guidance around the end of February.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Repligen: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/repligen-q3-earnings-snapshot-110935702.html?ref=bullished.co) — Associated Press
- [Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates](https://finance.yahoo.com/healthcare/articles/repligen-rgen-q3-earnings-revenues-111503600.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Repligen Reports Third Quarter 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/10/27/3388843/24603/en/repligen-reports-third-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance.html?ref=bullished.co) — globenewswire.com

### More on Repligen

- [Repligen Says BioLife Deal Puts 2027 Revenue Above $1 Billion, But Calls It Not Formal Guidance](https://www.bullished.co/repligen-says-biolife-deal-puts-2027-revenue-above-1-billion-but-calls-it-not-formal-01990904/)
- [Repligen Lifts 2026 Revenue Outlook To $844 Million-$852 Million, Yet A $41.2 Million Writedown Drives A Quarterly Loss](https://www.bullished.co/repligen-lifts-2026-revenue-outlook-to-844-million-852-million-yet-a-41-2-million-0a3c1ffb/)
- [Repligen Closes BioLife Deal: $11.25 In Cash And 0.1442 Repligen Shares For Each BioLife Share](https://www.bullished.co/repligen-closes-biolife-deal-11-25-in-cash-and-0-1442-repligen-shares-for-each-biolife-1a5d37a5/)

[All Repligen (RGEN) coverage →](https://www.bullished.co/tag/rgen/)